MetaCap

Illumina Financial Ratios

NASDAQ: ILMNHealth CareMedical SpecialitiesUSD

278.17+13.60 (+5.14%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Illumina ratio analysis

Illumina earned a net margin of 19.6% in FY 2025, up from -28.0% a year earlier. Gross margin was 66.1% compared with a median of 68.0% over the prior 9 years. Return on equity reached 31.2%, meaning Illumina generated 0.31 dollars of profit for every dollar of shareholders' equity.

Debt-to-equity stood at 0.55 versus 0.63 the year before, and the current ratio was 2.08. At the end of FY 2025, ILMN traded at 24.8 times earnings; across the 7 fiscal years shown, its year-end P/E ranged from 24.8 to 80.9, with a median of 48.0. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.

Summary generated from market data by MetaCap's automated system. Methodology

Illumina financial ratios (annual)

Illumina annual financial ratios
RatioFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
P/E ratio (at fiscal year end)24.76———73.4380.8847.9652.1843.2040.57
Price / sales4.824.924.756.7412.2716.3313.4112.7911.287.64
Price / book7.689.063.734.685.1711.2710.3011.3511.298.33
Gross margin66.1%65.4%60.9%64.8%69.7%68.0%69.6%69.0%66.4%69.5%
Operating margin18.6%-19.1%-23.7%-91.2%-2.7%17.9%27.8%26.5%22.0%24.5%
Net margin19.6%-28.0%-25.8%-96.1%16.8%20.3%28.3%24.8%26.4%19.3%
Free cash flow margin21.4%16.2%6.3%2.3%7.4%27.5%23.8%25.4%20.5%21.6%
Return on equity (ROE)31.2%-51.5%-20.2%-66.7%7.1%14.0%21.7%22.0%26.4%21.1%
Return on assets (ROA)12.8%-19.4%-11.5%-35.9%5.0%8.6%13.7%11.9%13.8%10.8%
Debt / equity0.550.630.260.230.090.250.250.530.430.48
Current ratio2.081.781.661.282.483.606.692.493.993.29
Revenue growth-0.7%-2.9%-1.7%1.3%39.7%-8.6%6.3%21.1%14.8%8.0%
EPS growth———-655.6%13.3%-34.0%21.2%13.0%60.3%-1.0%

Related